Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 4/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26580902 | 0.80 | KDM4E (0.35) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL17339833 | 0.78 | HSD17B10 (0.38) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL26580903 | 0.78 | KDM4E (0.33) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL27117567 | 0.77 | NPC1 (0.37) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL8659437 | 0.76 | ALDH1A1 (0.35) | AKR1A1AKR1B1 | |
| SCHEMBL12371889 | 0.74 | KDM4E (0.36) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL26580901 | 0.73 | KDM4E (0.35) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL12109837 | 0.72 | MAPK1 (0.40) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL10586118 | 0.72 | KDM4E (0.33) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL5497048 | 0.72 | ALDH1A1 (0.61) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024181261-A1 | CHEMICAL-MECHANICAL POLISHING COMPOSITION AND POLISHING METHOD | JSR株式会社 | 2024-09-06 | — | — | WO | disclosed |
| CN-111321414-A | Surface treatment agent and use thereof | 日本帕卡濑精株式会社 | 2020-06-23 | — | — | CN | disclosed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1135124-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000032180-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885KDM4E 4022/4885 |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | AKR1A1 549/4885AKR1B1 499/4885KDM4E 3323/4885 |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885KDM4E 4022/4885 |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | GPR119, LIPA, LIPC | AKR1A1 138/4885AKR1B1 165/4885KDM4E 4022/4885 |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | AKR1A1 549/4885AKR1B1 499/4885KDM4E 3323/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | AKR1A1 203/4885AKR1B1 185/4885KDM4E 2602/4885 |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885KDM4E 4022/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | AKR1A1 475/4885AKR1B1 419/4885KDM4E 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.